Hepatitis D

Current Treatment Options in Gastroenterology

Volumn 10, Issue 6, 2007, Pages 456-463

  Koytak, Elif S ^b   Yurdaydin, Cihan ^b   Glenn, Jeffrey S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; FAMCICLOVIR; HUMORAL THYMUS FACTOR; INTERFERON; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DELTA AGENT HEPATITIS; DEVELOPED COUNTRY; DISEASE COURSE; DRUG MEGADOSE; ENDEMIC DISEASE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; INFECTION CONTROL; LIVER CELL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; REVIEW; RNA INTERFERENCE; RNA VIRUS; TROPICS; VIRION; VIRUS ASSEMBLY;

EID: 37349023196     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0045-8     Document Type: Review

References (68)

1. Rizzetto M, Canese MG, Arico S, et al.: Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977, 18:997-1003.
2. Rizzetto M, Canese MG, Gerin JL, et al.: Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980, 141:590-602.
3. Rizzetto M, Purcell RH, Gerin JL: Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet 1980, 1:1215-1218.
4. Zakim D, Boyer TD: Hepatology: A Textbook of Liver Disease, edn 4, vol 2. Philadelphia: Saunders; 2003:997-1116.
5. Farci P: Delta hepatitis: an update. J Hepatol 2003, 39(Suppl 1):S212-S219.
6. Hsieh TH, Liu CJ, Chen DS, Chen PJ: Natural course and treatment of hepatitis D virus infection. J Formos Med Assoc 2006, 105:869-881.
7. Husa P, Linhartova A, Nemecek V, Husova L: Hepatitis D. Acta Virol 2005, 49:219-225.
8. Rizzetto M, Smedile A: Hepatitis D. In Diseases of the Liver, edn 9, vol 1. Edited by Schiff ER, Sorrell MF, Maddrey WC: Philadelphia: Lippincott Williams & Wilkins; 2003:863-875.
9. Lee CM, Changchien CS, Chung JC, Liaw YF: Characterization of a new genotype II hepatitis delta virus from Taiwan. J Med Virol 1996, 49:145-154.
10. Casey JL, Niro GA, Engle RE, et al.: Hepatitis B virus (HBV)/ hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996, 174:920-926.
11. Radjef N, Gordien E, Ivaniushina V, et al.: Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004, 78:2537-2544.
12. Quintero A, Uzcategui N, Loureiro CL, et al.: Hepatitis delta virus genotypes I and III circulate associated with hepatitis B virus genotype F in Venezuela. J Med Virol 2001, 64:356-359.
13. Su CW, Huang YH, Huo TI, et al.: Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006, 130:1625-1635.
14. Wu JC, Chen CM, Sheen IJ, et al.: Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995, 346:939-941.
15. Niro GA, Rosina F, Rizzetto M: Treatment of hepatitis D. J Viral Hepat 2005, 12:2-9.
16. Rizzetto M, Durazzo M: Hepatitis delta virus (HDV) infections. Epidemiological and clinical heterogeneity. J Hepatol 1991, 13(Suppl 4):S116-S118.
17. Sagnelli E, Gaeta GB, Felaco FM, et al.: Hepatitis C virus infection in households of anti-HCV chronic carriers in Italy: a multicentre case-control study. Infection 1997, 25:346-349.
18. Gaeta GB, Stroffolini T, Chiaramonte M, et al.: Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000, 32:824-827.
19. Huo TI, Wu JC, Lin RY, et al.: Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J Gastroenterol Hepatol 1997, 12:747-751.
20. Wedemeyer H, Heidrich B, Manns MP: Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 2007, 45:1331-1332.
21. Liaw YF, Chiu KW, Chu CM, et al.: Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study. J Infect Dis 1990, 162:1170-1172.
22. Wu JC, Chen CM, Sheen IJ, et al.: Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology 1995, 22:1656-1660.
23. Niro GA, Casey JL, Gravinese E, et al.: Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol 1999, 30:564-569.
24. Guilhot S, Huang SS, Xia YP, et al.: Expression of hepatitis delta virus large and small antigens in transgenic mice. J Virol 1994, 68:1052-1058.
25. Nisini R, Paroli M, Accapezzato D, et al.: Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997, 71:2241-2251.
26. Aslan N, Yurdaydin C, Wiegand J, et al.: Cytotoxic CD4+ T cells in viral hepatitis. J Viral Hepat 2006, 13:505-514.
27. Chang J, Gudima SO, Tarn C, et al.: Development of a novel system to study hepatitis delta virus genome replication. J Virol 2005, 79:8182-8188.
28. Fattovich G, Boscaro S, Noventa F, et al.: Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987, 155:931-935.
29. Fattovich G, Giustina G, Christensen E, et al.: Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000, 46:420-426.
30. Wu JC, Chen TZ, Huang YS, et al.: Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995, 108:796-802.
31. Rosina F, Conoscitore P, Cuppone R, et al.: Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999, 117:161-166.
32. Samuel D, Muller R, Alexander G, et al.: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329:1842-1847.
33. Smedile A, Casey JL, Cote PJ, et al.: Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998, 27:1723-1729.
34. Sharmeen L, Kuo MY, Dinter-Gottlieb G, Taylor J: Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol 1988, 62:2674-2679.
35. Farci P: Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 2006, 44:536-539.
36. Farci P, Mandas A, Coiana A, et al.: Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994, 330:88-94.
37. Madejon A, Cotonat T, Bartolome J, et al.: Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994, 19:1331-1336.
38. Gaudin JL, Faure P, Godinot H, et al.: The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995, 15:45-52.
39. di Bisceglie AM: Interferon therapy for chronic viral hepatitis. N Engl J Med 1994, 330:137-138.
40. Farci P, Roskams T, Chessa L, et al.: Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
41. Lau DT, Kleiner DE, Park Y, et al.: Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999, 117:1229-1233.
42. Di Marco V, Giacchino R, Timitilli A, et al.: Long-term interferon-alfa treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996, 3:123-128.
43. Yurdaydin C, Bozkaya H, Karaaslan H, et al.: A pilot study of two years of interferon in patients with chronic delta hepatitis. J Viral Hepat 2007, In press.
44. Gunsar F, Akarca US, Ersoz G, et al.: Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005, 10:721-726.
45. Niro GA, Ciancio A, Gaeta GB, et al.: Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44:713-720.
46. Erhardt A, Gerlich W, Starke C, et al.: Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006, 26:805-810.
47. Castelnau C, Le Gal F, Ripault MP, et al.: Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-735.
48. Wedemeyer H, Yurdaydin C, Dalekos G, et al.: 72 week data of the HIDIT-1 trial: multicenter randomized study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis [abstract]. J Hepatol 2007, 46:S4.
49. Yurdaydin C, Bozkaya H, Onder FO, et al.: Treatment of chronic delta hepatitis with lamivudine vs. lamivudine plus interferon vs. interferon. J Viral Hepat 2007, In press.
50. Marzano A, Ottobrelli A, Spezia C, et al.: Treatment of early chronic delta hepatitis with lymphoblastoid alpha interferon: a pilot study. Ital J Gastroenterol 1992, 24:119-121.
51. Wolters LM, van Nunen AB, Honkoop P, et al.: Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000, 7:428-434.
52. Canbakan B, Senturk H, Tabak F, et al.: Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006, 21:657-663.
53. Kaymakoglu S, Karaca C, Demir K, et al.: Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005, 49:1135-1138.
54. Rasshofer R, Choi SS, Wolfl P, Roggendorf M: Interference of antiviral substances with replication of hepatitis delta virus RNA in primary woodchuck hepatocytes. Prog Clin Biol Res 1991, 364:223-234.
55. Garripoli A, Di Marco V, Cozzolongo R, et al.: Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994, 14:154-157.
56. Lau DT, Doo E, Park Y, et al.: Lamivudine for chronic delta hepatitis. Hepatology 1999, 30:546-549.
57. Niro GA, Ciancio A, Tillman HL, et al.: Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005, 22:227-232.
58. Werle-Lapostolle B, Bowden S, Locarnini S, et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2006, 126:1750-1758.
59. Zoulim F: New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005, 42:302-308.
60. Yurdaydin C, Bozkaya H, Gurel S, et al.: Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002, 37:266-271.
61. Casey J, Cote PJ, Toshkov IA, et al.: Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrob Agents Chemother 2005, 49:4396-4399.
62. Rosina F, Conoscitore P, Smedile A, et al.: Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. Dig Liver Dis 2002, 34:285-289.
63. Glenn JS, Marsters JC, Jr, Greenberg HB: Use of a prenylation inhibitor as a novel antiviral agent. J Virol 1998, 72:9303-9306.
64. Bordier BB, Marion PL, Ohashi K, et al.: A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002, 76:10465-10472.
65. Bordier BB, Ohkanda J, Liu P, et al.: In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003, 112:407-414.
66. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999, 17:3631-3652.
67. Sklan EH, Glenn JS: The power of silence: application of small interfering RNAs to gastrointestinal diseases. Gastroenterology 2007, 132:2291-2295.
68. Chang J, Taylor JM: Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J Virol 2003, 77:9728-9731.